Cyclooxygenase inhibitors not inhibit resting lung cancer A549 cell proliferation

被引:30
作者
Duan, Weigang [1 ]
Zhang, Luyong [1 ]
机构
[1] China Pharmaceut Univ, Jiangsu Ctr Drug Screening, Nanjing 210038, Peoples R China
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2006年 / 74卷 / 05期
关键词
D O I
10.1016/j.plefa.2006.02.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Cyclooxygenase (COX) inhibitors were regarded as anticarcinogenic agents for lung cancer at least partly via PGE(2); but these were based on cytokin stimulation experiment on A549 cell. In order to clarify whether COX inhibitors directly inhibit A549 cell, three COX inhibitors, NS398 (selective COX-2 inhibitor), SC560 (selective COX-1 inhibitor), and acetyl salicylic acid (ASA, non-selective COX inhibitor), were studied. NS398, and ASA(,) can inhibit PGE(2) generation via COX-2 inhibition. The viability of A549 cell was assayed by MTT. However, without cytokin stimulation, all the three inhibitors (NS398 0.2-20 mu M: SC560 1.0-100nM; ASA 0.01-1.0 mM) were not able to inhibit A549 cell proliferation, in the other way round. NS398 promoted cell growth. And arachidonic acid (AA) and lipopolysaccharide (LPS) did not disturb the property of its growth. These data suggested that without cytokin stimulation. COX and PGE(2) may not be the kernel molecules involved in A549 cell proliferation. and COX inhibitors could not inhibit A549 cell growth directly. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:317 / 321
页数:5
相关论文
共 31 条
[1]
Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells [J].
Asano, K ;
Lilly, CM ;
Drazen, JM .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1996, 271 (01) :L126-L131
[2]
Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition [J].
Avis, I ;
Martínez, A ;
Tauler, J ;
Zudaire, E ;
Mayburd, A ;
Abu-Ghazaleh, R ;
Ondrey, F ;
Mulshine, JL .
CANCER RESEARCH, 2005, 65 (10) :4181-4190
[3]
Differential effects of prostaglandin derived from ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion [J].
Bagga, D ;
Wang, L ;
Farias-Eisner, R ;
Glaspy, JA ;
Reddy, ST .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1751-1756
[4]
Castaño E, 2000, J PHARMACOL EXP THER, V293, P509
[5]
IL-1β-dependent activation of NF-κB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase [J].
Catley, MC ;
Chivers, JE ;
Cambridge, LM ;
Holden, N ;
Slater, DM ;
Staples, KJ ;
Bergmann, MW ;
Loser, P ;
Barnes, PJ ;
Newton, R .
FEBS LETTERS, 2003, 547 (1-3) :75-79
[6]
Phorbol 12-myristate 13-acetate upregulates cyclooxygenase-2 expression in human pulmonary epithelial cells via Ras, Raf-1, ERK, and NF-κB, but not p38 MAPK, pathways [J].
Chang, MS ;
Chen, BC ;
Yu, MT ;
Sheu, JR ;
Chen, TF ;
Lin, CH .
CELLULAR SIGNALLING, 2005, 17 (03) :299-310
[7]
Relationship between expression and distribution of cyclooxygenase-2 and bcl-2 in human gastric adenocarcinoma [J].
Chen, Xiao-Li ;
Su, Bao-Shan ;
Sun, Run-Qin ;
Zhang, Jun ;
Wang, Yi-Li .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (08) :1228-1231
[8]
Investigation into the involvement of phospholipases A2 and MAP kinases in modulation of AA release and cell growth in A549 cells [J].
Choudhury, QG ;
Mckay, DT ;
Flower, RJ ;
Croxtall, JD .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (02) :255-265
[9]
Denkert C, 2001, CANCER RES, V61, P303
[10]
Antiatherogenic effects of Phyllanthus emblica associated with corilagin and its analogue [J].
Duan, WG ;
Yu, Y ;
Zhang, LY .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2005, 125 (07) :587-591